African Journal of
Biochemistry Research

  • Abbreviation: Afr. J. Biochem. Res.
  • Language: English
  • ISSN: 1996-0778
  • DOI: 10.5897/AJBR
  • Start Year: 2007
  • Published Articles: 427

Full Length Research Paper

Plasmodium berghei ANKA: Selection of pyronaridine resistance in mouse model

Kimani S K*
  • Kimani S K*
  • School of Pure and Applied Sciences, Karatina University, P.O Box 1957-10101, Karatina, Kenya.
  • Search for this author on:
  • Google Scholar
Ng’ang’a J K
  • Ng’ang’a J K
  • Department of Biochemistry, Jomo Kenyatta University of Agriculture and Technology P. O. Box 62000, 00200, Nairobi, Kenya.
  • Search for this author on:
  • Google Scholar
Kariuki D W
  • Kariuki D W
  • Department of Biochemistry, Jomo Kenyatta University of Agriculture and Technology P. O. Box 62000, 00200, Nairobi, Kenya.
  • Search for this author on:
  • Google Scholar
Kinyua J
  • Kinyua J
  • Department of Biochemistry, Jomo Kenyatta University of Agriculture and Technology P. O. Box 62000, 00200, Nairobi, Kenya.
  • Search for this author on:
  • Google Scholar
Kimani F T
  • Kimani F T
  • Kenya Medical Research Institute, Centre for Biotechnology Research and Development, P.O Box 54840-00200, Nairobi, Kenya.
  • Search for this author on:
  • Google Scholar
Kiboi D M
  • Kiboi D M
  • Department of Biochemistry, Jomo Kenyatta University of Agriculture and Technology P. O. Box 62000, 00200, Nairobi, Kenya. Kenya Medical Research Institute, Centre for Traditional Medicine and Drug Research P.O Box 54840-00200, Nairobi, Kenya.
  • Search for this author on:
  • Google Scholar


  •  Received: 19 May 2014
  •  Accepted: 12 June 2014
  •  Published: 15 August 2014

Abstract

Pyronaridine is a partner drug in, Pyramax®, a combination of artesunate (ASN)-pyronaridine (PRD) which was recently prequalified by WHO drug as a potential alternative for treatment of malaria in African setting. Pyronaridine is a mannich base, with a long half-life, thus predisposed to resistance. In this study, we selected pyronaridine resistance by submitting Plasmodium berghei ANKA line in vivo to increasing pyronaridine concentration for 20 successive passages over a period of six months. The effective doses that reduce parasitaemia by 50% (ED50) and 90% (ED90) determined in the standard four-day suppressive test for the parent line were 1.83 and 4.79 mgkg-1, respectively. After 20 drug pressure passages, the ED50 and ED90 increased by 66 and 40 fold, respectively. After dilution cloning, the parasites were grown in the absence of drug for five passages and cryo-preserving them at -80°C for at least one month, the resistance phenotypes remained stable. Thus, the resistant phenotype line could be used to explore genetic determinants associated with pyronaridine resistance; therefore, this strain represents a vital tool to study the mechanisms of resistance.

Key words: Malaria, pyronaridine, Pyramax®, resistance, Plasmodium berghei ANKA.

Abbreviation

Abbreviations: ASN, Artesunate; GFP, green fluorescent protein; PRDR; pyronaridine resistant clone.

Copyright © 2025 Author(s) retain the copyright of this article.

This article is published under the terms of the Creative Commons Attribution License 4.0

Back to Vol. 8 No. 6
Back to articles
SUBSCRIBE TO RSS
SUBMIT MANUSCRIPT
CONFERENCES